Matt O'Brien

Piper Sandler | Healthcare

Matt O'Brien is an analyst from Piper Sandler specializing in the Healthcare sector. Ranked #1727 out of 4580 analysts, they have issued 23 stock ratings with a success rate of 83.76% and an average return of 16.05%.

Matt O'Brien has a well-established track record, with 23 ratings issued in the Healthcare sector. They have consistently delivered a success rate of 83.76% and an average return of 16.05%, underscoring their expertise and ability to identify winning opportunities for investors.

#1727

Out of 4580

23

Total Ratings

+83.76%

Success Rate

+16.05%

Average Return

Recent Ratings Analysis

TNDM

Mar 17, 2026

Target

$33.00

Current

$21.91

Performance

%

Matt O'Brien rated TNDM as Overweight on Mar 17, 2026, setting a price target of 33. Shares have remained stable near 21.91, leaving the 33 target still in play.

CNMD

Mar 17, 2026

Target

$39.00

Current

$37.41

Performance

%

On Mar 17, 2026, CNMD was given a Neutral rating by Matt O'Brien, with a target price of 39. Market indecision, reflected in sideways trading near 37.41, supported the cautious call.

PRCT

Feb 26, 2026

Target

$50.00

Current

$27.99

Performance

18.45%

PRCT received a Overweight rating from Matt O'Brien on Feb 26, 2026, aiming for 50. Momentum has favored the Buy call, with shares climbing from 27.99 to 27.99, rewarding those who trusted the recommendation.

TMDX

Feb 25, 2026

Target

$160.00

Current

$124.70

Performance

-5.42%

On Feb 25, 2026, Matt O'Brien published a Overweight outlook on TMDX, with a target of 160. Market action contradicted the Buy thesis, as shares slipped to 124.7.

GMED

Jan 08, 2026

Target

$115.00

Current

$85.76

Performance

-9.36%

Matt O'Brien on Jan 08, 2026 assigned GMED a Overweight rating, with a price target of 115. The call has struggled to gain traction, with shares losing 9.36%.

KMTS

Dec 12, 2025

Target

$30.00

Current

$19.26

Performance

-26.40%

On Dec 12, 2025, Matt O'Brien reaffirmed KMTS with a Overweight rating, targeting 30. Shares slid 26.40% despite the recommendation, highlighting downside risks.

TELA

Nov 14, 2025

Target

$1.25

Current

$0.74

Performance

-26.37%

TELA was rated Neutral by Matt O'Brien on Nov 14, 2025, with a price objective of 1.25. Investors who stayed cautious avoided some of the 26.37% decline.

SI

Nov 12, 2025

Target

$18.00

Current

$15.28

Performance

1.87%

On Nov 12, 2025, Matt O'Brien initiated coverage on SI with a Overweight rating and target of 18. Neutral price movement of 1.87% leaves room for interpretation.

ATEC

Oct 31, 2025

Target

$25.00

Current

$12.60

Performance

-33.65%

Matt O'Brien issued a Overweight recommendation for ATEC on Oct 31, 2025, price target set at 25. The market hasn’t rewarded the bullish outlook, exposing uncertainty in the call.

DXCM

Oct 31, 2025

Target

$75.00

Current

$66.34

Performance

13.95%

On Oct 31, 2025, DXCM was evaluated by Matt O'Brien, who gave a Overweight rating and target of 75. This case illustrates how a timely bullish rating can translate into tangible gains of 13.95%.

BBNX

Oct 29, 2025

Target

$32.00

Current

$10.87

Performance

-59.43%

Matt O'Brien rated BBNX as Overweight on Oct 29, 2025, setting a price target of 32. The stock has underperformed, dropping 59.43% despite the bullish target of 32.

ITGR

Oct 24, 2025

Target

$82.00

Current

$84.12

Performance

15.38%

On Oct 24, 2025, ITGR was given a Overweight rating by Matt O'Brien, with a target price of 82. The stock rallied 15.38% after the rating, narrowing the gap to the target of 82 and validating the bullish stance.

KIDS

Oct 10, 2025

Target

$22.00

Current

$17.11

Performance

4.97%

KIDS received a Overweight rating from Matt O'Brien on Oct 10, 2025, aiming for 22. Price action was muted, as shares hovered around 17.11 despite the bullish outlook.

CARL

Aug 18, 2025

Target

$18.00

Current

$11.70

Performance

-11.23%

On Aug 18, 2025, Matt O'Brien published a Overweight outlook on CARL, with a target of 18. Market action contradicted the Buy thesis, as shares slipped to 11.7.

SGHT

Mar 06, 2025

Target

$3.50

Current

$3.74

Performance

50.20%

Matt O'Brien on Mar 06, 2025 assigned SGHT a Neutral rating, with a price target of 3.5. Shares outperformed expectations, climbing 50.20% despite the neutral view.

TFX

Feb 28, 2025

Target

$140.00

Current

$109.23

Performance

-17.72%

On Feb 28, 2025, Matt O'Brien reaffirmed TFX with a Neutral rating, targeting 140. The Hold stance reflected market caution that was later justified.

PODD

Feb 21, 2025

Target

$310.00

Current

$224.66

Performance

-20.56%

PODD was rated Overweight by Matt O'Brien on Feb 21, 2025, with a price objective of 310. This case shows how bullish projections can fail, with the stock now below 224.66.

PEN

Feb 19, 2025

Target

$330.00

Current

$336.21

Performance

10.68%

On Feb 19, 2025, Matt O'Brien initiated coverage on PEN with a Overweight rating and target of 330. The stock’s climb of 10.68% since the call highlights the foresight in the rating.

ATRC

Feb 13, 2025

Target

$50.00

Current

$30.44

Performance

-23.11%

Matt O'Brien issued a Overweight recommendation for ATRC on Feb 13, 2025, price target set at 50. The market hasn’t rewarded the bullish outlook, exposing uncertainty in the call.

STAA

Feb 12, 2025

Target

$16.00

Current

$18.08

Performance

9.71%

On Feb 12, 2025, STAA was evaluated by Matt O'Brien, who gave a Neutral rating and target of 16. Investors who stayed in despite the Hold saw upside of 9.71%.

CVRX

Feb 05, 2025

Target

$20.00

Current

$7.87

Performance

-47.81%

Matt O'Brien rated CVRX as Overweight on Feb 05, 2025, setting a price target of 20. The stock has underperformed, dropping 47.81% despite the bullish target of 20.

BSX

Feb 03, 2025

Target

$115.00

Current

$69.79

Performance

-32.29%

On Feb 03, 2025, BSX was given a Overweight rating by Matt O'Brien, with a target price of 115. Despite the Buy call, shares fell from 69.79 to 69.79, challenging the optimistic stance.

GKOS

Jan 27, 2025

Target

$180.00

Current

$98.94

Performance

-36.99%

GKOS received a Overweight rating from Matt O'Brien on Jan 27, 2025, aiming for 180. The rating hasn’t played out as hoped, with the stock trading 36.99% below expectations.

MDT

Aug 21, 2024

Target

$90.00

Current

$88.24

Performance

0.80%

On Aug 21, 2024, Matt O'Brien published a Neutral outlook on MDT, with a target of 90. Sideways action left the Hold view intact, with no major move since 88.24.

CUTR

Jun 21, 2024

Target

$3.00

Current

$0.10

Performance

-93.71%

Matt O'Brien on Jun 21, 2024 assigned CUTR a Neutral rating, with a price target of 3. The call successfully avoided chasing as shares lost 93.71%.

RCEL

May 14, 2024

Target

$9.00

Current

$4.62

Performance

-47.02%

On May 14, 2024, Matt O'Brien reaffirmed RCEL with a Neutral rating, targeting 9. The Hold stance reflected market caution that was later justified.

FNA

May 09, 2024

Target

$15.00

Current

$13.09

Performance

58.67%

FNA was rated Overweight by Matt O'Brien on May 09, 2024, with a price objective of 15. A bullish response from the market helped close the gap of 1.91 to the target.

SYK

May 01, 2024

Target

$380.00

Current

$349.56

Performance

6.53%

On May 01, 2024, Matt O'Brien initiated coverage on SYK with a Overweight rating and target of 380. The stock’s climb of 6.53% since the call highlights the foresight in the rating.

Frequency Asked Questions

Who is Matt O'Brien?

Matt O'Brien is an analyst from Piper Sandler specializing in the Healthcare sector.

What is Matt O'Brien's success rate?

Matt O'Brien currently has a success rate of +83.76%.

How many ratings has Matt O'Brien issued?

Matt O'Brien has issued 23 stock ratings so far.

What is the average return of Matt O'Brien's calls?

Their stock ratings have generated an average return of +16.05%.

What is Matt O'Brien's ranking?

Matt O'Brien is ranked #1727 out of 4580 analysts.

What types of ratings does Matt O'Brien give?

Their ratings include Buy, Hold, and Sell recommendations, depending on the stock’s outlook.

How can I follow Matt O'Brien?

You can follow Matt O'Brien by clicking the "Follow Analyst" button on this page to receive updates on their stock calls.

What is the most recent rating by Matt O'Brien?

Their latest rating was a Buy on TNDM issued on 2026-03-17.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep